Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Telix Pharmaceuticals (TLX) Non-Current Debt (2023 - 2025)

Telix Pharmaceuticals has reported Non-Current Debt over the past 3 years, most recently at $391.9 million for Q4 2025.

  • Quarterly Non-Current Debt rose 8.6% to $391.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $391.9 million through Dec 2025, up 8.6% year-over-year, with the annual reading at $391.9 million for FY2025, 14.66% up from the prior year.
  • Non-Current Debt was $391.9 million for Q4 2025 at Telix Pharmaceuticals, up from $360.9 million in the prior quarter.
  • Over five years, Non-Current Debt peaked at $391.9 million in Q4 2025 and troughed at $5.3 million in Q4 2023.
  • The 3-year median for Non-Current Debt is $360.9 million (2024), against an average of $252.7 million.
  • Year-over-year, Non-Current Debt skyrocketed 6652.77% in 2024 and then rose 8.6% in 2025.
  • A 3-year view of Non-Current Debt shows it stood at $5.3 million in 2023, then surged by 6652.77% to $360.9 million in 2024, then rose by 8.6% to $391.9 million in 2025.
  • Per Business Quant, the three most recent readings for TLX's Non-Current Debt are $391.9 million (Q4 2025), $360.9 million (Q4 2024), and $5.3 million (Q4 2023).